@endattack1
The Multicenter Stage II Trial involving Ipilimumab and also Nivolumab throughout Unresectable or even Metastatic Metaplastic Breast cancers: Cohort 36 associated with Dual Anti-CTLA-4 and Anti-PD-1 Restriction throughout Rare Malignancies (DART, SWOG S1609).